Evaluation of an Intravitreal Fluocinolone Acetonide Implant versus Standard Systemic Therapy in Noninfectious Posterior Uveitis

Ophthalmology

Volumn 117, Issue 3, 2010, Pages

  Pavesio, Carlos ^a   Zierhut, Manfred ^b   Bairi, Khaled ^c   Comstock, Timothy L ^c   Usner, Dale W ^c  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c BAUSCH AND LOMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUOCINOLONE ACETONIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CATARACT; CATARACT EXTRACTION; CHILD; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONINFECTIOUS POSTERIOR UVEITIS; PHAKIC INTRAOCULAR LENS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETINA DETACHMENT; SCHOOL CHILD; SUSTAINED DRUG RELEASE; SYSTEMIC THERAPY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS;

EID: 77049097118     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.11.027     Document Type: Article

References (28)

1. Durrani O.M., Tehrani N.N., Marr J.E., et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88 (2004) 1159-1162
2. Gritz D.C., and Wong I.G. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111 (2004) 491-500
3. Durrani O.M., Meads C.A., and Murray P.I. Uveitis: a potentially blinding disease. Ophthalmologica 218 (2004) 223-236
4. Rothova A., Suttorp-van Schulten M.S., Frits Treffers W., and Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80 (1996) 332-336
5. Darrell R.W., Wagener H.P., and Kurland L.T. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 68 (1962) 502-514
6. Goldstein H. The reported demography and causes of blindness throughout the world. Adv Ophthalmol 40 (1980) 1-99
7. Suttorp-Schulten M.S., and Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 80 (1996) 844-848
8. Forrester J., Okada A., and BenEzra D. Posterior segment intraocular inflammation: International Ocular Inflammation Society Guidelines: Series 2, v. 184 (1998), Kugler Publications, The Hague 68
9. Sansoretti A., and Safran A. Uveitis recent development. Med Hyg 53 (1995) 144-149
10. Jaffe G.J., Ben-Nun J., Guo H., et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 107 (2000) 2024-2033
11. McCluskey P.J., Towler H.M., and Lightman S. Management of chronic uveitis. BMJ 320 (2000) 555-558
12. Jaffe G.J., Martin D., Callanan D., et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113 (2006) 1020-1027
13. Callanan D.G., Jaffe G.J., Martin D.F., et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: 3-year clinical trial results. Arch Ophthalmol 126 (2008) 1191-1201
14. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119 (2001) 1417-1436
15. Howe L.J., Stanford M.R., Edelsten C., and Graham E.M. The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis. Eye 8 (1994) 443-447
16. Jabs D.A., Rosenbaum J.T., Foster C.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130 (2000) 492-513
17. Nussenblatt R., Whitcup S., and Palestine A.G. Uveitis: Fundamentals and Clinical Practice. St Louis: Mosby (1996) 58-68
18. Goldstein D.A., Godfrey D.G., Hall A., et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 125 (2007) 1478-1485
19. Becker M.D., Smith J.R., Max R., and Fiehn C. Management of sight-threatening uveitis: new therapeutic options. Drugs 65 (2005) 497-519
20. Bernstein H.N., Mills D.W., and Becker B. Steroid-induced elevation of intraocular pressure. Arch Ophthalmol 70 (1963) 15-18
21. Gillies M.C., Simpson J.M., Billson F.A., et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 122 (2004) 336-340
22. Holekamp N.M., Thomas M.A., and Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol 139 (2005) 421-428
23. Singh I.P., Ahmad S.I., Yeh D., et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 138 (2004) 286-287
24. Smithen L.M., Ober M.D., Maranan L., and Spaide R.F. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 138 (2004) 740-743
25. McGhee C.N.J., Dean S., and Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Safety 25 (2002) 33-55
26. Klein B.E., Klein R., and Moss S.E. Change in visual acuity associated with cataract surgery. The Beaver Dam Eye Study. Ophthalmology 103 (1996) 1727-1731
27. Hogan M.J., Kimura S.J., and Thygeson P. Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol 47 (1959) 155-170
28. Nussenblatt R.B., Palestine A.G., Chan C.C., and Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92 (1985) 467-471